ARVN News and Press, Arvinas Inc. From 03/20/24

2024-03-20 18:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-19 02:19:43 ET Clinical-stage biotechnology company Arvinas ( NASDAQ: ARVN ) appointed Noah Berkowitz, M.D., Ph.D., to the role of chief medical officer and a member of the executive committee reporting to president and CEO John Houston, Ph.D. effective tod...

NEW HAVEN, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Noah Berkowitz, M.D., Ph.D., to the role of Chief Medical Officer and a...

2024-03-10 15:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

2024-02-29 02:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – ...

2024-02-23 08:39:04 ET More on Pfizer Pfizer's Post-Pandemic Pivot Pfizer: Turnaround Is Gaining Momentum Pfizer Stock: It's Time To Buy The Dip Obesity drugs to expand U.S. GDP by 1% in the coming years: Goldman Sachs Pfizer to settle Lipitor antitru...

2024-02-20 16:14:18 ET More on Arvinas Arvinas: Positive Breast Cancer Data Leads To Other Developments Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Citi downgrades Arvinas to neutral, cites valuation Pfizer, Arvinas...

- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of dru...